{"abstract": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "web_url": "https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-could-get-its-moneys-worth-out-of-anacor-deal.html", "snippet": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "lead_paragraph": "Pfizer\u2019s $5.2 billion offer for Anacor Pharmaceuticals, announced on Monday, dodges the drug giant\u2019s bigger issue. The company may have made a good deal for Anacor, the maker of eczema and toenail-fungus remedies, even though it\u2019s paying a 55 percent premium. The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Could Get Its Money\u2019s Worth Out of Anacor Deal", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Anacor Pharmaceuticals Inc", "rank": 4, "major": "N"}], "pub_date": "2016-05-16T18:31:45+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Antony Currie", "person": [{"firstname": "Antony", "middlename": null, "lastname": "Currie", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5", "word_count": 363, "uri": "nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5"}